{{Short description|Serious adverse event of vaccine candidates}}
'''Vaccine-associated enhanced respiratory disease (VAERD)''', or simply '''enhanced respiratory disease''' (ERD), is an adverse event where an [[Exacerbation|exacerbated]] [[Course (medicine)|course of respiratory disease]] occurs with higher [[Incidence (epidemiology)|incidence]] in the vaccinated population than in the [[control group]]. It is a barrier against vaccine development that can lead to its failure.<ref name="AcostaCaballero2016">{{cite journal|last1=Acosta|first1=Patricio L.|last2=Caballero|first2=Mauricio T.|last3=Polack|first3=Fernando P.|last4=Papasian|first4=C. J.|year=2016|title=Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease|journal=Clinical and Vaccine Immunology|volume=23|issue=3|pages=189–195|doi=10.1128/CVI.00609-15|pmid=26677198 |pmc=4783420 |issn=1556-6811|doi-access=free}}</ref>

Immunologically, VAERD is characterized with an exaggerated [[Th2]] response and [[eosinophilic]] pulmonary [[Infiltration (medical)|infiltrations]].<ref name="BadenEl Sahly2021" /> It may result from [[Antibody-mediated complement deposition|antibody-mediated complement activation]] followed by weak [[Neutralization (immunology)|neutralization]].<ref name="CompansOldstone2014">{{cite book|author1=Richard W. Compans|url=https://books.google.com/books?id=aDvBBAAAQBAJ|title=Influenza Pathogenesis and Control - Volume I|author2=Michael B. A. Oldstone|date=8 October 2014|publisher=Springer|isbn=978-3-319-11155-1|pages=315–320}}</ref>

Historical instances of the phenomenon were seen in vaccine candidates for [[respiratory syncytial virus]] (RSV), [[SARS-CoV]], [[Middle East Respiratory Syndrome]] (MERS), and some [[influenza]] strains.<ref name="AcostaCaballero2016" /><ref name="AgrawalTao2016">{{cite journal|last1=Agrawal|first1=Anurodh Shankar|last2=Tao|first2=Xinrong|last3=Algaissi|first3=Abdullah|last4=Garron|first4=Tania|last5=Narayanan|first5=Krishna|last6=Peng|first6=Bi-Hung|last7=Couch|first7=Robert B.|last8=Tseng|first8=Chien-Te K.|year=2016|title=Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus|journal=Human Vaccines & Immunotherapeutics|volume=12|issue=9|pages=2351–2356|doi=10.1080/21645515.2016.1177688|pmid=27269431 |pmc=5027702 |issn=2164-5515|doi-access=free}}</ref><ref name="BottazziStrych2020">{{cite journal|last1=Bottazzi|first1=Maria Elena|last2=Strych|first2=Ulrich|last3=Hotez|first3=Peter J.|last4=Corry|first4=David B.|year=2020|title=Coronavirus vaccine-associated lung immunopathology-what is the significance?|journal=Microbes and Infection|volume=22|issue=9|pages=403–404|doi=10.1016/j.micinf.2020.06.007|pmid=32599077 |issn=1286-4579|pmc=7318931}}</ref> Thus, [[COVID-19 vaccine clinical research]] involved [[Monitoring (medicine)|monitoring]] for VAERD because the vaccine target, [[SARS-CoV-2]], belongs to [[Coronavirus|the same viral subfamily as SARS-CoV and MERS]]. The effect was not shown in [[phase III clinical trials]] for [[Tozinameran]] or for the [[Moderna vaccine]].<ref name="BadenEl Sahly2021">{{cite journal|last1=Baden|first1=Lindsey R.|last2=El Sahly|first2=Hana M.|last3=Essink|first3=Brandon|last4=Kotloff|first4=Karen|last5=Frey|first5=Sharon|last6=Novak|first6=Rick|last7=Diemert|first7=David|last8=Spector|first8=Stephen A.|last9=Rouphael|first9=Nadine|last10=Creech|first10=C. Buddy|last11=McGettigan|first11=John|year=2021|title=Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine|journal=New England Journal of Medicine|volume=384|issue=5|pages=403–416|doi=10.1056/NEJMoa2035389 | pmc=7787219 |issn=0028-4793|first15=Adam|last35=Ivarsson|last30=Knightly|first30=Conor|last31=Leav|first31=Brett|last32=Deng|first32=Weiping|last33=Zhou|first33=Honghong|first35=Melanie|first28=Hamilton|first29=Rolando|last29=Pajon|last36=Miller|first36=Jacqueline|last37=Zaks|first37=Tal|first14=Joel|last14=Solis|first13=Nathan|last13=Segall|first12=Shishir|last12=Khetan|last34=Han|last16=Fierro|first34=Shu|last22=Follmann|first16=Carlos|last17=Schwartz|first17=Howard|last18=Neuzil|first18=Kathleen|last19=Corey|first19=Larry|last20=Gilbert|first20=Peter|last21=Janes|last28=Bennett|last15=Brosz|first22=Dean|last23=Marovich|first23=Mary|last24=Mascola|first24=John|author24-link=John R. Mascola |last25=Polakowski|first25=Laura|last26=Ledgerwood|first26=Julie|last27=Graham|first27=Barney S.|first21=Holly|pmid=33378609 |doi-access=free}}</ref><ref>{{cite report|url=https://www.fda.gov/media/144337/download|title=FDA Review of Efficacy and Safety of Pfizer-BioNTech COVID-19 Vaccine Emergency Use Authorization Request|date=10 December 2020|access-date=11 December 2020|format=PDF|website=U.S. [[Food and Drug Administration]] (FDA)}}</ref>

== References ==
<references />

[[Category:Vaccination]]
[[Category:Drug-induced diseases]]